Bayer's Rivaroxaban Submitted for Approval in Japan
- Details
- Category: Bayer
![Bayer Bayer](/images/stories/logo/bayer.gif)
Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease
- Details
- Category: Genzyme
![Genzyme Genzyme](/images/stories/logo/genzyme.gif)
Forest Laboratories Completes Acquisition of Clinical Data, Inc.
- Details
- Category: Business
![Forest Laboratories Forest Laboratories](/images/stories/logo/forest.gif)
Nycomed acquires distribution rights to product portfolio in Turkey
- Details
- Category: Nycomed
![Nycomed Nycomed](/images/stories/logo/nycomed.gif)
Novartis discontinues clinical trial of Tasigna®
- Details
- Category: Novartis
![Novartis Novartis](/images/stories/logo/novartis_b.gif)
Boehringer Ingelheim maintains sales level/course set for the future: product pipeline well-filled
- Details
- Category: Boehringer Ingelheim
![Boehringer Ingelheim Boehringer Ingelheim](/images/stories/logo/boehringeringelheim.gif)
Pfizer and Medivation Announce Results from Phase 3 HORIZON Trial of Dimebon in Huntington Disease
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/stories/logo/pfizer_b.gif)
More Pharma News ...
- Bayer and Regeneron Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
- Amgen Establishes Commercial Operations in Brazil
- Novartis sells global rights to Elidel®, a medicine to treat atopic dermatitis
- FDA approves orphan drug vandetanib
- Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation
- Pfizer to Sell Capsugel to KKR
- Boehringer Ingelheim's lead hepatitis C compound moves into phase III